When vascular injury is observed in dogs used in preclinical toxicology studies, careful evaluation of the lesions is warranted, especially when differentiating drug-induced vascular changes from spontaneous findings, such as idiopathic canine polyarteritis. The clinical signs as well as the nature and distribution of lesions can often be distinguishing, as is the case with vasoactive drugs, including vasodilators and/or positive inotropes (hydralazine, minoxidil, endothelin receptor antagonists, and phosphodiesterase III inhibitors). For most types of vasodilator-induced vascular injury, the lesion is often restricted to coronary arteries, whereas in idiopathic canine polyarteritis, arterial lesions not only involve coronary arteries, but also medium to small arteries of other organs. In addition, the nature of the changes in vessels yields important clues. Medial and adventitial hemorrhage is generally associated with vasodilator-induced arterial lesion, whereas hemorrhage is generally absent in idiopathic polyarteritis. Although idiopathic canine polyarteritis can generally be differentiated from vasoactive-induced vascular injury in dogs, there are increasing incidences of this type of polyarteritis in dogs receiving any 1 of a number of unrelated classes of compounds, suggestive of an exacerbation of the spontaneous disease. Therefore, in order to differentiate drug-induced injury from idiopathic canine polyarteritis, it is critical that examination of the vascular pathology be conducted with good understanding of clinical, pharmacological, and mechanistic data associated with the drug.
INTRODUCTION
The term vasculitis is commonly used to describe changes that occur in the blood vessel wall and surrounding tissues and features varying degrees of inflammatory cell infiltration, mural necrosis, and lumen occlusion. In this article, the term vascular injury is used instead of vasculitis because inflammation is not always a prominent feature of certain vascular injuries, especially acute ones induced by vasoactive drugs. It has empirically been shown that vascular injury can be mediated through primary cytotoxicity, activation of the immune system, or by excessive hemodynamic activity. Most of the reported cases of vascular injury in dogs have been attributed to functional damage associated with hemodynamic changes. Unlike humans, immune-mediated causes of vascular injury in dogs are not commonly reported.
In evaluation of vascular injury in preclincial toxicology studies in dogs, it is important to be familiar with the spontaneous vascular changes that can complicate the evaluation of drug-related vascular changes, especially if these spontaneous findings, like idiopathic canine polyarteritis, are morphologically similar to drug-induced vascular injury. The scope of this article is to summarize the main morphological patterns of drug-induced vascular injury, primarily those caused by vasoactive drugs, and to discuss how they can be differentiated from idiopathic canine polyarteritis of Beagle dogs. Table 1 summarizes the microscopic features of major inflammatory manifestations of drug-induced vascular injury of dogs that include the following: 1) vasoactive arteriopathy; 2) toxic vasculitis; and 3) hypersensitivity vasculitis. The vasoactive arteriopathy is seen more commonly in dogs and is described in more detail later as well as in reviews by Joseph et al (25) , Greaves et al (12, 13) , and Boor et al (4) .
DRUG-INDUCED VASCULAR INJURY

Vasoactive Induced Arterial Lesions in the Dog
Dogs appear to be particularly sensitive to developing arterial changes associated with treatment with various types of vasoactive drugs despite varying chemical structures and pharmacological activities ( Table 2 ). The vascular changes elicited by vasoactive drugs at excessive dosages in dogs often have distinctive morphology, which is demonstrated by a vasodilator and/or positive inotropic-induced lesion that is seen with high doses of phosphodiesterase (PDE)-III inhibitors (SK&F 94120, SF&K 94836, SK&F 95654, and SK&F 94418) (17, (22) (23) (24) (25) . Arterial lesions induced by these PDE-III inhibitors are time-dependent. Acute segmental changes of medial necrosis and hemorrhage of coronary arteries predominated during the first 7 days of administration and was followed by more chronic proliferative changes in the intima (smooth muscle hyperplasia with mucoid ground substance) and adventitia (fibroplasia) at days 9-30 (22) . Medial degeneration and necrosis, adventitial edema, and variable inflammation, can also be associated with chronic proliferative phase of PDE III induced coronary arterial damage (22) . Arterial changes induced by PDE III inhibitors are limited in distribution to coronary arteries in which both right and 26 CLEMO ET AL TOXICOLOGIC PATHOLOGY (24, 25) . Structurally unrelated vasodilators and/or positive inotropes, including the adenosine agonist CI-947 (36), hydralazine (35) , minoxidil (33), theobromine (11), adrenergic inotropes (isoproterenol, norepinephrine, and dopamine) (41) , and various types of endothelin receptor antagonists (2, 31, 47, 49) , have been reported to induce, in coronary arteries of dogs, an acute lesion that is morphologically similar to that described for PDE III inhibitors. Administration of CI-1020, an endothelin A receptor antagonist, resulted in medial smooth muscle necrosis and hemorrhage of extramural coronary arteries in dogs treated with single to multiple intravenous doses ( Figure 1a ) (2) . These acute arterial changes are reversed by day 29 after treatment cessation; however, in dogs treated with CI-1020 for 4 weeks, the arterial lesions progressed to chronic proliferative or chronic-active lesions characterized by medial smooth muscle hypertrophy, necrosis and/or fibrosis with mixed inflammatory cell infiltrates ( Figure 1b ) (2) . Like CI-1020, the acute arterial changes are reversible when treatment is discontinued for minoxidil (33) and the PDE III inhibitor SF&K 95654 (24) . The arterial changes associated with vasodilator administration in dogs are probably the consequence of hemodynamic changes related to pharmacological activity on the cardiovascular system rather than direct toxicity. It has been postulated that these lesions are the result of disturbances in critical wall tension due to vasodilator-related relaxation of the medial smooth muscle (23, 33, 34) . Direct evidence of an effect on vascular wall tension is not available for many of the vasodilators reported to induce vascular lesions, but increased coronary blood flow has been demonstrated for minoxidil (21, 33) , hydralazine (9), endothelin receptor antagonist (32) , and PDE III inhibitor SK&F 94836 (15) .
In dogs, a variety of hypertensive vasoconstrictor agents ( Table 2) can also elicit characteristic arterial changes in the heart, as well as other organs (6, 14, 51) . Intense vasoconstriction may be the principle cause of medial necrosis of coronary arteries of dogs treated with excessive doses of digoxin (6, 48) . Unlike vasodilators, vasoconstrictors primarily affect small caliber arteries in multiple organs and are characterized of medial fibrinoid necrosis with minimal hemorrhage.
Other Types of Drug-Induced Vascular Injury
Toxic necrotizing vasculitis can be induced in dogs by direct damage to the tunica media and/or endothelium. Morphologic features of toxic vasculitis are often indistinguishable from classic polyarteritis nodosa and include acute changes of fibrinoid necrosis and neutrophilic inflammation and chronic changes of focal scarring of media, adventitial fibrosis, and intimal proliferation with luminal narrowing (Table 1) . Systemic administrations of monocrotaline and mitomycin C have been reported to produce vascular damage by having a primary effect on the endothelium (4). Vascular smooth muscle appears to be the primary target of allylamine admin-istration in dogs that caused progressive edema, necrosis, hyalinization, medial hypertrophy, and subintimal proliferation of small and medium muscular arteries (4, 5, 10) . Unlike the vasodilators, the major coronary arteries are generally not affected by allylamine.
Immune-mediated vascular injury also occurs in dogs and has been associated with several drugs, including itraconazole, metronidazole, trimethoprim/sulfamethoxazole, and carprofen (30, 38) . Immune complex disease (the Arthus reactions) resulting from a type III hypersensitivity response is sometimes implicated in dogs with drug-induced vascular lesions. Type III hypersensitivity results from antibody response to drugs or drug/metabolites covalently bound to proteins that give rise to deposition of immune-complexes in small vessels. An immune-mediated reaction that is probably playing a larger role in induction of vascular injury in dogs 28 CLEMO ET AL TOXICOLOGIC PATHOLOGY is the Type IV delayed hypersensitivity response (50) . This type of hypersensitivity response is neither dose-nor timedependent and is morphologically characterized by mononuclear leukocytic infiltrate (± eosinophils) without necrotizing lesions of the vessel wall (Table 1) . With the increased use of biological drugs (cytokines, proteins, and other immunomodulating drugs), the incidence of these immune-mediated vascular injuries may increase in dogs as it has in humans (8) .
For some drugs, the mechanism of vascular injury is not clearly apparent. This is the case following nonnucleoside reverse transcriptase inhibitor (NNRTI) administration in dogs, which is associated with vascular injury of small-to mediumsized muscular arteries in multiple organs (Pfizer Inc; unpublished results). The extramural coronary arteries are the most frequently affected site. The early stages (<1 week) of arterial damage are characterized predominantly by macrophages within the adventitia and perivascular tissue with subendothelial inflammatory cells, fibrinoid necrosis, and a few neutrophils within the vessel wall. During later stages, arterial changes consist of variable rupture of internal elastic lamina, thickening of tunica media by connective tissue and smooth muscle, and accumulation of mononuclear cells. To date, no clear hemodynamic changes or immune-mediated changes have been observed with these NNRTI associated arterial changes.
SPONTANEOUS VASCULAR INJURY IN DOG
Unlike humans, the spectrum of spontaneous arterial lesions is narrow in the dog and falls into three main patterns, including degenerative, proliferative, and inflammatory (Table 3 ). Spontaneous arterial diseases of the dog have been described by Kelly (26) who pointed out that degenerative and proliferative arterial diseases are either age-related or have well-recognized associations with other diseases. In dogs, inflammatory vascular changes have been caused by a variety of infectious agents (bacteria, fungi, and parasites) or immunemediated processes (3, 38, 39) , but these spontaneous lesions are rarely encountered in nonclinical safety assessment studies, given the pathogen-free status of the dogs. One type of spontaneous arterial change that can pose problems in evaluating potential drug-induced vascular changes is idiopathic polyarteritis of Beagle dogs.
Idiopathic Polyarteritis of Beagle Dogs
Idiopathic canine polyarteritis is a term suggested by Kerns et al (29) to describe an acute to chronic spontaneous arterial disease of unknown etiology that is primarily found in laboratory Beagle dogs. Many investigators throughout the world have described this syndrome as Beagle pain syndrome (19) , juvenile polyarteritis syndrome (44) , necrotizing vasculitis (7, 43, 46) , polyarteritis (1, 16, 27) , arteritis (18, 37) , periarteritis (45) , panarteritis (28, 40) , and idiopathic febrile necrotizing arteritis (19) . The specific clinical and morphological presentation of this syndrome will vary, depending upon the stage of disease. Clinically, the disease is characterized by recurrent episodes of fever, body weight loss, and cervical pain manifested by a stiff gait and neck with hunched body position. In some dogs, these clinical signs are not detected, even though acute, subacute, or chronic microscopic arterial lesions are observed in multiple organs (7, 16, 19, 28, 44) . In the acute febrile phase, typical changes in clinical pathology data include leukocytosis with neutrophilia, elevated acute phase proteins (α-2-globulin and fibrinogen), hypoalbuminemia, elevated platelet counts, and mild regenerative anemia (43) . Interleukin-6 has also been reported to be elevated during the acute phase (20) . The etiology of this syndrome is unknown at this time. Immune-mediated injury has been suspected, but has not been reliably confirmed by immunohistochemical or immune functions studies.
The morphological appearance of arterial lesions depends upon the number of febrile episodes and the duration between the most recent febrile episode and the point at which the samples were collected. Histologically, idiopathic canine polyarteritis manifests itself as an acute to chronic polysystemic arterial disease that affects small to medium muscular arteries in multiple organs ( Table 4 ). The arteries most consistently affected were found in the heart, the cranial mediastinum, and the cervical spinal meninges (44) . In the heart, the extramural branches of the right coronary artery are affected more frequently (29, 44) . Snyder et al (44) described the acute arterial changes as ranging from histiocytic-lymphocytic periarteritial infiltration to transmural neutrophilic inflammation with medial fibrinoid necrosis (Figure 2a ). Thrombosis can sometimes be seen in acute arterial changes. Subacute and chronic lesions from dogs in remission are characterized by intimal hyperplasia and medial hypertrophy with varying degrees of ruptured internal elastic laminae and perivascular mononuclear inflammation (Figure 2b In evaluation of the acute arterial changes associated with idiopathic canine polyarteritis and high dose of vasodilators and/or positive inotropes, the overall profile of histopathology, site predilection, and clinical and laboratory changes can often be differentiating (Table 4 ). For most vasodilatorinduced arterial lesions associated with hydralazine (35), minoxidil (33) , and PDE III inhibitors (22) (23) (24) (25) , the location is restricted to the coronary arteries (primarily the right extramural branch, but the left extramural and intramural branches can also be affected). In idiopathic canine polyarteritis, the arterial lesions not only involve extramural coronary arteries, but medium to small arteries of other organs. The vasodilator-induced acute arterial change is characterized by medial and adventitial hemorrhage with minimal inflammation while, during the acute phase of idiopathic canine polyarteritis, prominent periarterial and arterial inflammation without hemorrhage is generally observed. Fibrinoid necrosis and thrombus formation are seen more often in idiopathic canine polyarteritis (44) . The acute arterial changes produced by vasodilators are often associated with myocardial changes whereas idiopathic canine polyarteritis does not usually have accompanying myocardial changes. Additionally, distinct clinical signs of episodic fever and cervical pain will allow one to differentiate idiopathic canine polyarteritis from vasodilator-induced vascular changes, in that the latter may be associated with clinical hemodynamic changes (tachycardia and hypotension) rather than febrile episodes. Problems can arise in differentiating drug-induced from spontaneous vascular changes in the dog, especially when the drug-induced change presents only as an increased incidence of lesions that are histologically indistinguishable from that of idiopathic canine polyarteritis. This is especially true when dealing with chronic to chronic-active arterial changes, associated with continous treatement with such drugs as endothelin receptor antagonists (CI-1020) (2), minodoxil (33) , and NNRTI (Pfizer Inc; unpublished data). In such instances, the presence of a dose-response relationship may be the only distinguishing feature that suggests an association with the drug. It has also been suggested that hemodynamic stresses caused by administration of vasodilators (22, 25) may potentate the development of idiopathic polyarteritis. Immunomodulating drugs may also potentiate the appearance of this spontaneous vascular change in dogs (46) . Benzodiazepine may also be re-lated to the enhancement of idiopathic polyarteritis in Beagle dogs (42) . Moreover, it should also be recognized that drugs not designed to have pharmacological cardiovascular effects might be secondarily vasoactive and induce similar arterial lesions.
MAIN POINTS TO CONSIDER IN EVALUATING VASCULAR
CHANGES IN PRECLINICAL DOG TOXICITY STUDIES The finding of vascular injury, especially arterial lesions, should be investigated carefully in preclinical dog toxicity studies, regardless of whether it is dose-dependent. When vascular injury is observed in toxicity studies, the clinical presentation and lesion distribution and histological features can suggest potential mechanisms. A detailed morphologic description can help to distinguish different mechanisms of drug-induced vascular changes from each other as well as from idiopathic canine polyarteritis (Tables 1 and 4 ). It is important to understand the mechanism of vascular injury, especially in identification of changes in hemodynamic status or immune function. Specific mechanistic studies may be indicated in those cases where hemodynamic alterations are suspected of causing the vascular injury. Other things to consider when evaluating vascular injury in dogs includes the following: 1) reversibility of lesion; 2) presence of lesion in another species; 3) dose-response; 4) drug pharmacokinetics, pharmacodynamics, and pharmacological activity; 5) therapeutic indication and dose.
During recent years, the regulatory agencies have become more critical of preclinical vascular findings in animals, especially when the mechanism of action is unknown. By considering the points addressed in the previous paragraph, toxicologists and pathologists can better assess the risk of preclinical vascular changes to humans, as demonstrated in the development of minoxidil. In dogs, minoxidil-induced coronary arterial lesions were not considered a large risk for humans because it was shown to be the result of exaggerated hemodynamic pharmacology, seen only at high doses that would not be used in humans (33, 34) .
SUMMARY
Vascular injury in preclinical toxicology studies in dogs can be properly assessed by careful interpretation of the clinical and histopathologic data and by understanding the possible mechanisms of vascular injury. The classic hemorrhagic, necrotizing acute arterial changes observed in the tunica media of coronary arteries of dogs treated with high doses of vasodilator and/or positive inotropic drugs can generally be differentiated from the background occurrence of idiopathic canine polyarteritis. However, it becomes a challenge to manage dose-dependent increases in arterial changes that are morphologically similar to idiopathic canine polyarteritis. This is particularly true for drug-induced chronic arterial changes that cannot be clearly differentiated from chronic lesions associated with idiopathic canine polyarteritis. It has also been proposed that subclinical hemodynamic changes associated with some types of drug treatment in the dog, a species that is uniquely sensitive to vascular injury of coronary artery, may lead to activation of idiopathic canine polyarteritis. Therefore, in order to differentiate drug-induced from spontaneous vascular injury in the dog, the vascular pathology has to be interpreted in the context of all clinical, pharmacological, and mechanistic data associated with the drug. Furthermore, additional research on mechanisms of drug-induced vascular injury and development of more specific and sensitive biomarkers for vascular injury will allow better management of this finding within preclinical toxicology studies.
